Marina A. Stukova

Saint Petersburg, SPE 197022, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Novel Intranasal Influenza-Vectored Vaccine Corfluvec Provides Protection Against Influenza and COVID-19, Mitigating SARS-CoV-2-Induced Lung Vascular Damage.

Novel Intranasal Influenza-Vectored Vaccine Corfluvec Provides Protection Against Influenza and COVID-19, Mitigating SARS-CoV-2-Induced Lung Vascular Damage.

Journal: Vaccines
Published: July 01, 2026

A CXCL10-Expressing Influenza Vector Induces Robust Adaptive Immunity Despite Strong Attenuation.

A CXCL10-Expressing Influenza Vector Induces Robust Adaptive Immunity Despite Strong Attenuation.

Journal: Pharmaceutics
Published: May 15, 2026

Neomycin Exhibits Immunomodulatory and Antiviral Activity Against Influenza B Virus.

Neomycin Exhibits Immunomodulatory and Antiviral Activity Against Influenza B Virus.

Journal: Viruses
Published: March 12, 2026

SARS-CoV-2 and Influenza Co-Circulation and Co-Vaccination: A Narrative Review.

SARS-CoV-2 and Influenza Co-Circulation and Co-Vaccination: A Narrative Review.

Journal: Vaccines
Published: January 12, 2026

Pre-Exposure Intranasal Treatment with Neomycin Sulfate Reduces Transmission of Influenza B Virus.

Pre-Exposure Intranasal Treatment with Neomycin Sulfate Reduces Transmission of Influenza B Virus.

Journal: Antibiotics (Basel, Switzerland)
Published: December 31, 2025

Novel Intranasal Replication-Deficient NS1ΔC Flu Vaccine Confers Protection from Divergent Influenza A and B Viruses in Mice.

Novel Intranasal Replication-Deficient NS1ΔC Flu Vaccine Confers Protection from Divergent Influenza A and B Viruses in Mice.

Journal: Vaccines
Published: December 09, 2025

Influenza Vaccine Immunogenicity in Hemodialysis Patients.

Influenza Vaccine Immunogenicity in Hemodialysis Patients.

Journal: Vaccines
Published: December 01, 2025

The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence.

The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence.

Journal: International journal of molecular sciences
Published: July 05, 2025

Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice.

Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice.

Journal: Vaccines
Published: December 05, 2024

Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice.

Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice.

Journal: Vaccines
Published: December 03, 2024

Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.

Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.

Journal: Vaccines
Published: October 25, 2024

Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2.

Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2.

Journal: Vaccines
Published: August 14, 2024
Showing 1-12 of 53

Last Updated: 09/26/2026